Published in J Immunol on June 01, 2008
Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe (2008) 11.08
New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol (2009) 5.57
The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol (2011) 5.41
IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med (2010) 4.65
The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol (2010) 4.06
IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med (2010) 4.04
Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature (2012) 3.48
IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A (2008) 3.04
T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol (2010) 2.94
A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A (2009) 2.46
Transcriptional regulatory networks in Th17 cell differentiation. Curr Opin Immunol (2009) 2.12
IL-21 mediates suppressive effects via its induction of IL-10. J Immunol (2009) 2.00
The effects of IL-6 on CD4 T cell responses. Clin Immunol (2008) 1.90
The many faces of Th17 cells. Curr Opin Immunol (2011) 1.84
Th17 cells: from precursors to players in inflammation and infection. Int Immunol (2009) 1.77
IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. Blood (2009) 1.67
Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev (2010) 1.61
IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani. J Clin Invest (2009) 1.53
T(H)17 cytokines in autoimmune neuro-inflammation. Curr Opin Immunol (2011) 1.40
Inflammatory Bowel Disease: How Effective Is TNF-α Suppression? PLoS One (2016) 1.39
Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov (2010) 1.36
NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. Am J Pathol (2008) 1.35
Induction of regulatory Tr1 cells and inhibition of T(H)17 cells by IL-27. Semin Immunol (2011) 1.24
Elevated interleukin-21 correlated to Th17 and Th1 cells in patients with immune thrombocytopenia. J Clin Immunol (2009) 1.18
Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity. J Clin Invest (2015) 1.14
IL-21 and IL-21 receptor expression in lymphocytes and neurons in multiple sclerosis brain. Am J Pathol (2011) 1.11
Development, regulation and functional capacities of Th17 cells. Semin Immunopathol (2010) 1.10
Th17 cytokines and vaccine-induced immunity. Semin Immunopathol (2010) 1.07
IL-21 restricts virus-driven Treg cell expansion in chronic LCMV infection. PLoS Pathog (2013) 1.03
Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. Blood (2011) 0.98
Signal transduction and Th17 cell differentiation. Microbes Infect (2009) 0.98
Cytokine mediators of Th17 function. Eur J Immunol (2009) 0.97
Key role for IL-21 in experimental autoimmune uveitis. Proc Natl Acad Sci U S A (2011) 0.94
Translational mini-review series on Th17 cells: are T helper 17 cells really pathogenic in autoimmunity? Clin Exp Immunol (2009) 0.93
Bhlhe40 controls cytokine production by T cells and is essential for pathogenicity in autoimmune neuroinflammation. Nat Commun (2014) 0.93
Cytokine control of inflammation and repair in the pathology of multiple sclerosis. Yale J Biol Med (2012) 0.92
Th1 and Th17 Cells in Tuberculosis: Protection, Pathology, and Biomarkers. Mediators Inflamm (2015) 0.91
Interleukin (IL)-21-independent pathogen-specific CD8+ T-cell expansion, and IL-21-dependent suppression of CD4+ T-cell IL-17 production. Immunology (2010) 0.90
Nuclear receptor NR4A2 orchestrates Th17 cell-mediated autoimmune inflammation via IL-21 signalling. PLoS One (2013) 0.87
Upregulated IL-21 and IL-21 receptor expression is involved in experimental autoimmune uveitis (EAU). Mol Vis (2009) 0.86
IL-21 promotes lupus-like disease in chronic graft-versus-host disease through both CD4 T cell- and B cell-intrinsic mechanisms. J Immunol (2012) 0.86
Th17 cell cytokine secretion profile in host defense and autoimmunity. Inflamm Res (2011) 0.85
Altered effector CD4+ T cell function in IL-21R-/- CD4+ T cell-mediated graft-versus-host disease. J Immunol (2010) 0.85
IL-28 supplants requirement for T(reg) cells in protein sigma1-mediated protection against murine experimental autoimmune encephalomyelitis (EAE). PLoS One (2010) 0.85
The Emerging Role of Interleukin-21 in Transplantation. J Clin Cell Immunol (2012) 0.81
IL-21R expression on CD8+ T cells promotes CD8+ T cell activation in coxsackievirus B3 induced myocarditis. Exp Mol Pathol (2012) 0.81
Endogenous interleukin-6 amplifies interleukin-17 production and corticoid-resistance in peripheral T cells from patients with multiple sclerosis. Immunology (2014) 0.80
A deleterious role for Th9/IL-9 in hepatic fibrogenesis. Sci Rep (2016) 0.79
IL-21 and T Cell Differentiation: Consider the Context. Trends Immunol (2016) 0.79
IL-21R signaling is critical for induction of spontaneous experimental autoimmune encephalomyelitis. J Clin Invest (2015) 0.79
Role of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosis. Mediators Inflamm (2015) 0.78
Cellular and Molecular Dynamics of Th17 Differentiation and its Developmental Plasticity in the Intestinal Immune Response. Front Immunol (2017) 0.77
Interleukin-21 signaling in B cells, but not in T cells, is indispensable for the development of collagen-induced arthritis in mice. Arthritis Res Ther (2016) 0.77
Deficiency of the immunostimulatory cytokine IL-21 promotes intestinal neoplasia via dysregulation of the Th1/Th17 axis. Oncoimmunology (2016) 0.75
Higher efficacy of anti-IL-6/IL-21 combination therapy compared to monotherapy in the induction phase of Th17-driven experimental arthritis. PLoS One (2017) 0.75
Targeting Th17 Cells with Small Molecules and Small Interference RNA. Mediators Inflamm (2015) 0.75
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
NKT cells: what's in a name? Nat Rev Immunol (2004) 7.84
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature (2002) 5.98
CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature (2007) 5.31
Immune surveillance of tumors. J Clin Invest (2007) 5.04
Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol (2003) 4.66
IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med (2010) 4.65
CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol (2006) 4.48
The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer (2008) 4.42
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med (2010) 4.04
Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol (2002) 3.96
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73
MR1 presents microbial vitamin B metabolites to MAIT cells. Nature (2012) 3.71
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood (2010) 3.23
Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol (2002) 3.20
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A (2008) 3.19
A natural killer T (NKT) cell developmental pathway iInvolving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage. J Exp Med (2002) 3.13
Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol (2006) 3.04
TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation. Nat Immunol (2005) 3.00
IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol (2007) 2.99
A network of PDZ-containing proteins regulates T cell polarity and morphology during migration and immunological synapse formation. Immunity (2005) 2.97
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 2.88
Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med (2005) 2.83
Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol (2005) 2.77
A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med (2002) 2.73
Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood (2002) 2.72
BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med (2007) 2.70
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A (2010) 2.67
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med (2012) 2.66
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res (2013) 2.62
Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. Immunity (2009) 2.61
Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res (2011) 2.59
Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci U S A (2008) 2.57
Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature (2009) 2.54
Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol (2003) 2.48
Recognition of β-linked self glycolipids mediated by natural killer T cell antigen receptors. Nat Immunol (2011) 2.42
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A (2011) 2.35
A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med (2005) 2.32
Recognition of CD1d-restricted antigens by natural killer T cells. Nat Rev Immunol (2012) 2.32
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30
NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. J Immunol (2007) 2.26
Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol (2011) 2.21
A molecular basis for the exquisite CD1d-restricted antigen specificity and functional responses of natural killer T cells. Immunity (2011) 2.11
Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med (2006) 2.10
CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol (2006) 2.10
Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol (2005) 2.08
Humans lack iGb3 due to the absence of functional iGb3-synthase: implications for NKT cell development and transplantation. PLoS Biol (2008) 2.08
Innate immunity defines the capacity of antiviral T cells to limit persistent infection. J Exp Med (2010) 2.06
Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells. J Exp Med (2013) 2.04
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res (2011) 2.03
IL-21 induces the functional maturation of murine NK cells. J Immunol (2004) 2.00
DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med (2008) 2.00
Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat Immunol (2007) 1.97
Functional subsets of mouse natural killer cells. Immunol Rev (2006) 1.95
Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol (2010) 1.94
NKT cells - conductors of tumor immunity? Curr Opin Immunol (2002) 1.94
A molecular basis for NKT cell recognition of CD1d-self-antigen. Immunity (2011) 1.94
Identification of Bcl-6-dependent follicular helper NKT cells that provide cognate help for B cell responses. Nat Immunol (2011) 1.94
Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med (2012) 1.93
Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood (2009) 1.91
Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med (2002) 1.88
Adaptability of the semi-invariant natural killer T-cell receptor towards structurally diverse CD1d-restricted ligands. EMBO J (2009) 1.88
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res (2011) 1.88
T cell receptor CDR2 beta and CDR3 beta loops collaborate functionally to shape the iNKT cell repertoire. Immunity (2009) 1.85
Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med (2002) 1.85
Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol (2007) 1.84
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood (2002) 1.83
TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood (2004) 1.83
Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res (2010) 1.82
The pre-metastatic niche: finding common ground. Cancer Metastasis Rev (2013) 1.82
Invariant NKT cells in hyperplastic skin induce a local immune suppressive environment by IFN-gamma production. J Immunol (2009) 1.81
Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat Immunol (2010) 1.81
Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol (2008) 1.75
The TIM gene family regulates autoimmune and allergic diseases. Trends Mol Med (2005) 1.74
Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med (2004) 1.73
Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim. Immunity (2009) 1.73
Structural insight into MR1-mediated recognition of the mucosal associated invariant T cell receptor. J Exp Med (2012) 1.71
Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res (2010) 1.71
Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol (2001) 1.70
The influence of CD1d in postselection NKT cell maturation and homeostasis. J Immunol (2005) 1.68